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MaBACKGROUND Troponins may be elevated in patients with pneumonia, but associations with myocardial infarction (MI)
and with platelet activation are still undefined.
OBJECTIVES The aim of this study was to investigate the relationship between troponin elevation and in vivo markers
of platelet activation in the early phase of hospitalization of patients affected by community-acquired pneumonia.
METHODS A total of 278 consecutive patients hospitalized for community-acquired pneumonia, who were followed up
until discharge, were included. At admission, platelet activation markers such as plasma soluble P-selectin, soluble
CD40 ligand, and serum thromboxane B2 (TxB2) were measured. Serum high-sensitivity cardiac troponin T levels and
electrocardiograms were obtained every 12 and 24 h, respectively.
RESULTS Among 144patientswith elevated high-sensitivity cardiac troponin T, 31 had signs ofMI and 113 did not. Baseline
plasma levels of soluble P-selectin and soluble CD40 ligand and serum TxB2 were significantly higher in patients who
developed signs of MI. Logistic regression analysis showed plasma soluble CD40 ligand (p< 0.001) and soluble P-selectin
(p<0.001), serum TxB2 (p¼0.030), mean platelet volume (p¼0.037), Pneumonia Severity Index score (p¼0.030), and
ejection fraction (p ¼ 0.001) to be independent predictors of MI. There were no significant differences in MI rate between
the 123 patients (45%) taking aspirin (100 mg/day) and those who were not aspirin treated (12% vs. 10%; p ¼ 0.649).
Aspirin-treated patients with MIs had higher serum TxB2 compared with those without MIs (p ¼ 0.005).
CONCLUSIONS MI is an early complication of pneumonia and is associated with in vivo platelet activation and serum
TxB2 overproduction; aspirin 100 mg/day seems insufficient to inhibit thromboxane biosynthesis. (MACCE in Hospitalized
Patients With Community-acquired Pneumonia; NCT01773863) (J Am Coll Cardiol 2014;64:1917–25) © 2014 by the
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ABBR EV I A T I ON S
AND ACRONYMS
ASA = acetylsalicylic acid
CAP = community-acquired
pneumonia
CHD = coronary heart disease
COPD = chronic obstructive
pulmonary disease
hs-cTnT = high-sensitivity
cardiac troponin T
IQR = interquartile range
MI = myocardial infarction
MPV = mean platelet volume
PAD = peripheral arterial
disease
PSI = Pneumonia Severity
Index
sCD40L = soluble CD40 ligand
sP-selectin = soluble
p-selectin
T2DM = type 2 diabetes
mellitus
TxB2 = thromboxane B2
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1918supported by studies indicating that influ-
enza vaccination is associated with reduced
risk for hospitalization for pneumonia, heart
disease, cerebrovascular disease, and the
risk for death from all causes during influenza
seasons in elderly patients (3).
A prospective study (4) focused attention
on the association of pneumonia with ele-
vations of cardiac enzymes (e.g., creatine
kinase-MB) and signs of myocardial ischemia,
suggesting that myocardial infarction (MI)
may be a complication of pneumonia in the
early phase of clinical presentation. More
recently, Chang et al. (5) showed elevated
serum troponins (a more sensitive marker of
cardiac damage than creatine kinase-MB) in
patients with pneumonia, but the relation-
ship with MI was not investigated. Further-
more, the mechanism of MI in patients with
pneumonia is still elusive.
Platelets play a key role in the occurrence
of MI, as shown by interventional trials
showing that acetylsalicylic acid (ASA),which inhibits platelet thromboxane A2 production
via irreversible acetylation of COX-1 (6), lowers car-
diovascular events in patients with acute or chronic
coronary heart disease (CHD) (7). In patients with
pneumonia or other infections, previous studies
showed in vivo elevation of platelet activation bio-
markers, suggesting potential interplay between
platelet overactivation and cardiovascular events
during pneumonia. Thus, we speculated that in
pneumonia, differences in platelet activation might
be detected in patients with and without signs of MI.
For this purpose, we performed a prospective study in
which the relationships between in vivo markers of
platelet activation were analyzed in the early phase of
hospitalization of patients affected by CAP. Markers
analyzed included plasma levels of soluble CD40
ligand (sCD40L) (8) and soluble P-selectin (sP-selec-
tin) (9); serum levels of thromboxane B2 (TxB2), which
reflects maximal platelet formation of thromboxane
A2 (10–12); and serum levels of high-sensitivity car-
diac troponin T (hs-cTnT).
METHODS
PATIENT SELECTION. The study was conducted at
4 centers of the University Hospital Policlinico
Umberto I (Rome, Italy). All patientswith CAP admitted
to the 4 units through the emergency department from
October 2011 to April 2013 were prospectively recruited
and followed up. After they gave written informed
consent, we enrolled 278 consecutive patients whofulfilled the following criteria in the study: 1) age $ 18
years; 2) clinical presentation of an acute illness with
one or more of the following signs or symptoms sug-
gesting CAP: presence of rales, rhonchi, bronchial
breath sounds, dullness, increased fremitus and ego-
phony, fever (>38.0C), tachycardia, chills, dyspnea,
coughing (productive or unproductive cough), and
chest pain; and 3) presence of new consolidation(s)
on chest x-ray. Pneumonia was considered CAP if it
was diagnosed on hospitalization and the patient had
not been discharged from an acute care facility
within 14 days preceding the clinical presentation.
Patients were excluded from the study if any of the
following criteria applied: radiographic evidence of
preexisting infiltrates, severe sepsis or immunosup-
pression (human immunodeficiency virus infection,
chemotherapy, high doses of immunosuppressive
agents such as prednisone), presence of malignancy,
pregnancy or breastfeeding, documented severe
allergy to antibiotics, and health care–associated
pneumonia (13).
BASELINE ASSESSMENT. Data on demographic charac-
teristics and comorbidities were collected. Severity of
illness at presentation was quantified by the Pneu-
monia Severity Index (PSI), a validated prediction
score for 30-day mortality in patients with CAP
(14). Immediately after diagnosis of CAP, routine
blood laboratory tests including platelet count and
mean platelet volume (MPV), serum hs-cTnT and
high-sensitivity C-reactive protein, serum TxB2, and
arterial blood gas test, were performed. There-
after, serum hs-cTnT was assessed every 12 h, and
12-lead electrocardiography was repeated every 24 h.
M-mode and 2-dimensional color Doppler echocardi-
ography was performed within 2 days of hospital
admission. Ejection fraction was measured using the
modified Simpson’s rule.
Type 2 diabetes mellitus (T2DM), hypertension,
history of CHD, dyslipidemia, peripheral arterial dis-
ease (PAD), and chronic obstructive pulmonary dis-
ease (COPD) were defined as previously described
(15–17). Baseline treatments were defined according
to patients’ pharmacological histories. Patients al-
ready treated with ASA before admission were cate-
gorized as ASA users. Compliance with ASA and other
medications was monitored daily.
This study was conducted according to the prin-
ciples stated in the Declaration of Helsinki. The
institutional review board approved this prospec-
tive, observational study, which was registered at
ClinicalTrials.gov (NCT01773863).
STUDY ENDPOINTS. The primary study end point
was the occurrence of MI during the hospital stay.
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1919MI criteria were those of the third universal defi-
nition of MI: the detection of an increase in cardiac
troponin with at least 1 value above the 99th per-
centile upper reference limit, associated with at least
1 of the following: 1) chest pain; 2) detection of new or
presumably new significant ST-segment–T-wave
changes or new left bundle branch block; 3) devel-
opment of pathological Q waves on electrocar-
diography; 4) de novo imaging evidence of viable
myocardium loss or regional wall motion abnormal-
ity; 5) identification of an intracoronary thrombus by
angiography or autopsy; and 6) cardiac death with
symptoms suggestive of myocardial ischemia and
presumed new ischemic electrocardiographic changes
or new left bundle branch block (18).
ST-segment elevation MI and non–ST-segment
elevation MI were defined as previously reported (18).
Therapeutic treatment at admission and during the
hospital stay were registered.
Adjudication of cardiovascular events was per-
formed by a committee of cardiologists (C.C. and A.C.)
who did not participate in patient recruitment and
follow-up and were unaware of any patient’s clinical
and laboratory characteristics.
PLASMA LEVELS OF sCD40L, sP-SELECTIN, AND
SERUM TXB2. Blood samples to measure biomarkers
of platelet activation were obtained within 24 h of
admission and at the end of hospitalization. Samples
with or without 3.8% sodium citrate were taken
without stasis from patients who had fasted for at
least 12 h.
After withdrawal of a first blood sample, 1-ml
serum aliquots were immediately transferred into
glass tubes and allowed to clot at 37C for 1 h. Serum
was separated by centrifugation and frozen at 80C
until assayed. Serum TxB2 was measured using an
enzyme-linked immunosorbent assay commercial kit
(R&D Systems, Inc., Minneapolis, Minnesota) and
expressed as nanograms per milliliter. Intra- and
interassay coefficients of variation for the TxB2 assay
kit were 5.9% and 8.9%, respectively.
Citrated samples were centrifuged to separate
plasma, which was frozen at 80C until assayed.
Plasma sCD40L and sP-selectin levels were measured
with a commercial immunoassay (Tema Ricerca,
Castenaso, Italy). Intra- and interassay coefficients of
variation were 5% and 7% for sCD40L and 4.3% and
6.1% for sP-selectin.
SERUM HS-cTNT MEASUREMENT. Hs-cTnT levels
were measured with the Elecsys 2010 (Roche Di-
agnostics, Indianapolis, Indiana) at a dedicated core
laboratory. According to the manufacturer, the
99th-percentile cutoff point for hs-cTnT is 0.014 mg/l,and a coefficient of variation of <10% is achieved
at 0.013 mg/l (19).
STATISTICAL ANALYSIS. Categorical variables are
reported as counts and percentages and continuous
variables as mean  SD or medians and interquartile
ranges (IQRs). Differences between percentages were
assessed by chi-square or Fisher exact tests. Student
unpaired t tests and analysis of variance were used for
normally distributed continuous variables. Appro-
priate nonparametric tests (Mann-Whitney, Kruskal-
Wallis, and Spearman rank correlation tests) were
used for all other variables.
To better define the relationships between TxB2,
sCD40L, and sP-selectin levels and cardiovascular
events, we grouped these continuous marker mea-
surements into 4 categories, with cutoffs on the basis
of quartiles of the observed measurements.
The bivariate and multivariate effects of prog-
nostic factors and treatments on the primary and
secondary endpoints were assessed by means of
logistic regression models. Wald confidence intervals
and tests for odds ratios and adjusted odds ratios
were computed on the basis of the estimated stan-
dard errors. In addition to TxB2, sCD40L, and
sP-selectin levels, possible independent variables
considered were age, sex, body mass index, PSI
score, ejection fraction, history of CHD or stroke,
T2DM, hypertension, renal failure, COPD, chronic or
paroxysmal atrial fibrillation, dyslipidemia, PAD,
high-sensitivity C-reactive protein, and use of statins
and ASA.
For multivariate models, model selection was
performed using forward stepwise regression on the
basis of the Akaike information criterion.
Variance inflation factors were computed to assess
collinearity for each predictor in the final multivariate
model, with a variance inflation factor < 2.5 consid-
ered safe. The variance inflation factor criterion was
satisfied in all reported models, hence there were no
collinearity issues.
TxB2, sCD40L, and sP-selectin levels evaluated at
the end of hospitalization were compared with base-
line levels by Wilcoxon rank sum tests.
Only p values <0.05 were regarded as statistically
significant. All tests were 2-tailed, and analyses were
performed using computer software packages (R
version 2.15.2, R Development Core Team, Vienna,
Austria).
Sample s i ze . The minimum sample size was com-
puted considering 1) an expected rate of MI of 5%
(20–24); 2) a relevant difference in TxB2 levels to be
detected between groups of jdj $ 50 ng/ml; 3) a SD
between the groups of 35 ng/ml; and 4) type I error
probability of a ¼ 0.05 and power of 1  b ¼ 0.90.
CAP patients (n=278)
Patients without signs of MI
(n=113)
Patients with signs of MI
(n=31)
Patients with
hs-cTnT>0.014 (n=144)
Patients with
hs-cTnT≤0.014 (n=134)
FIGURE 1 Study Flow Diagram
CAP ¼ community-acquired pneumonia; hs-cTnT ¼ high-
sensitivity cardiac troponin T; MI ¼ myocardial infarction.
TABLE 1 Patient Cha
Variable
Age, yrs
Men
BMI, kg/m2
Ejection fraction, %
Pre-existing comorbid
conditions
History of CHD
Previous stroke
T2DM
Hypertension
Renal failure
COPD
PAF
CAF
Peripheral artery
disease
Dyslipidemia
ASA
Statins
hs-CRP, ng/ml
PSI score
Platelet count
MPV, fl
sCD40L, ng/ml
sP-selectin, ng/ml
TxB2, ng/ml
Values are mean  SD, %,
ASA ¼ acetylsalicylic acid
CAP ¼ community-acquire
disease; hs-CRP ¼ high-s
myocardial infarction; MPV
fibrillation; PSI ¼ Pneumon
T2DM ¼ type 2 diabetes m
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1920This resulted in a sample size of 220 patients. The
expected event rate and TxB2 levels were obtained
by analyzing data from previous studies (25).racteristics
CAP With hs-cTnT
#0.014 mg/l
(n ¼ 134)
CAP With hs-cTnT
>0.014 mg/l
Without MI
(n ¼ 113)
CAP With hs-cTnT
>0.014 mg/l
and MI
(n ¼ 31) p Value
61.8  16.6 77.3  10.2 79.2  8.9 <0.001
62 65 58 0.742
26.4  4.1 26.6  3.8 26.8  3.6 0.875
56.4  6.2 49.7  10.4 43.9  8.6 <0.001
21 45 65 <0.001
11 9 23 0.104
16 31 32 0.015
58 79 84 0.001
4 33 29 <0.001
25 48 36 0.017
9 16 16 0.281
8 25 16 0.002
2 10 13 0.018
17 24 29 0.231
37 52 48 0.069
32 36 37 0.776
5.9 (2.7–12.8) 6.0 (3.3–12.7) 6.3 (3.5–11.6) 0.955
75  27 104  25 120  29 <0.001
223 (173–319) 238 (180–274) 237 (173–249) 0.767
8.3 (7.5–8.8) 8.6 (7.7–9.5) 9.4 (8.2–10.4) 0.001
3 (2.2–4.0) 3.2 (2.4–6.0) 10 (9.5–13) <0.001
15 (11–19) 22 (16–30) 37 (28–48) <0.001
108 (60–200) 106 (50–180) 200 (100–352) 0.004
or median (interquartile range).
; BMI ¼ body mass index; CAF ¼ chronic (persistent or permanent) atrial fibrillation;
d pneumonia; CHD ¼ coronary heart disease; COPD ¼ chronic obstructive pulmonary
ensitivity C-reactive protein; hs-cTnT ¼ high-sensitivity cardiac troponin T; MI ¼
¼ mean platelet volume; PAD ¼ peripheral artery disease; PAF ¼ paroxysmal atrial
ia Severity Index; sCD40L ¼ soluble CD40 ligand; sP-selectin ¼ soluble P-selectin;
ellitus; TxB2 ¼ thromboxane B2.RESULTS
We recruited 278 patients hospitalized for CAP (173
men, 105 women; mean age 70.0  15.7 years).
Most of the patients had arterial hypertension
(68%). Histories of CHD were present in 36% of
patients, previous strokes in 12%, T2DM in 24%,
COPD in 35%, PAD in 7%, and dyslipidemia in 21%.
Histories of paroxysmal atrial fibrillation were pre-
sent in 12% of patients, while 16% were affected by
chronic (persistent or permanent) atrial fibrillation,
and 18% had severe renal failure (i.e., glomerular
filtration rate <30 ml/min). Among the entire pop-
ulation, 123 patients (47%) were treated with ASA
100 mg/day.
Elevated serum levels of hs-cTnT (>0.014 mg/l;
median 0.042 mg/l; IQR: 0.024 to 0.116 mg/l) were
found in 144 of the patients with CAP (52%). Of these
144 patients, 113 had isolated hs-cTnT elevations, and
31 showed signs of MI (Figure 1). MI generally
occurred within 48 h of pneumonia clinical presen-
tation. Most MIs were non–ST-segment elevation MIs
(n ¼ 26), 2 were ST-segment elevation MIs, 3 were
fatal, and all but 2 had no chest pain.
Clinical characteristics of patients with CAP
without hs-cTnT elevation (median 0.010; IQR: 0.007
to 0.011 mg/l), patients with hs-cTnT elevation (me-
dian 0.033; IQR: 0.023 to 0.060 mg/l) without signs of
MI, and patients with troponin hs-cTnT elevation
(median 0.299; 0.165 to 0.556 mg/l) and signs of MI
are summarized in Table 1. Patients with hs-cTnT
elevation (whether or not they developed MIs) were
older and had a higher prevalence of COPD, chronic
atrial fibrillation, PAD, renal failure, and T2DM than
patients without hs-cTnT elevation.
Baseline plasma levels of sCD40L and sP-selectin,
serum TxB2, and MPV were significantly higher in
patients who developed signs of MI. Furthermore,
plasma sP-selectin levels were higher in patients with
isolated hs-cTnT but without signs of MI (p < 0.001)
(Table 1). When ASA users and nonusers were
considered separately, both sCD40L and sP-selectin
were significantly correlated with serum TxB2 in
ASA users (Rs ¼ 0.440; p < 0.001, and Rs ¼ 0.214;
p ¼ 0.020, respectively) and nonusers (Rs ¼ 0.269;
p ¼ 0.001, and Rs ¼ 0.258; p ¼ 0.001, respectively).
No significant differences in platelet count were
observed in patients with normal or elevated hs-
cTnT. Platelet count also did not correlate with
markers of platelet activation or serum TxB2 (not
shown).
To better define the magnitude of the relationship
between markers of platelet activation and MI,
patients with CAP were stratified into sCD40L,
30
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FIGURE 2 Intrahospital MI According to
In Vivo Platelet Activation Markers
Number of patients with CAP with intrahospital MI stratified
according to soluble CD40 ligand (sCD40L) (A), soluble
P-selectin (sP-selectin) (B), and thromboxane B2 (C) quartiles.
Other abbreviations as in Figure 1.
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1921sP-selectin, and TxB2 quartiles (Figure 2). The largest
number of MIs occurred in the upper quartiles of
all 3 variables, corresponding to sCD40L >6.0 ng/ml,
sP-selectin >26 ng/ml, and TxB2 >200 ng/ml.
In univariate analysis, age (p < 0.001), PSI score
(p < 0.001), ejection fraction (p < 0.001), history of
CHD (p < 0.001), previous stroke (p ¼ 0.040), hyper-
tension (p ¼ 0.044), sCD40L >6.0 ng/ml (p < 0.001),
sP-selectin >26 ng/ml (p < 0.001), TxB2 >200 ng/ml
(p ¼ 0.003), and MPV (p ¼ 0.001) were associated with
MI occurrence. By multivariate analysis, sCD40L,
sP-selectin, serum TxB2, MPV, PSI score, and ejection
fraction were independently associated with MI
(Table 2).
ASA AND THROMBOXANE. Among the 278 patients,
123 (45%) were treated with ASA 100 mg/day. The
rate of MI was 10% in ASA-untreated patients and
12% in ASA-treated patients (p ¼ 0.649). Patients
with long-term ASA use showed lower serum TxB2
levels than non-ASA-treated patients (median 61
ng/ml [IQR: 20 to 100 ng/ml] vs. 160 ng/ml [IQR: 106
to 247 ng/ml]; p < 0.001). Among ASA-untreated
patients; serum TxB2 levels were higher in those
who experienced MIs compared with those who did
not (p ¼ 0.001). Similar findings were detected in
ASA-treated patients; ASA-treated patients with MIs
had higher serum TxB2 values than ASA-untreated
patients (p ¼ 0.005) (Figure 3). Only 9 patients had
serum TxB2 <10 ng/ml, corresponding to full COX1
inhibition (26).
FOLLOW-UP OF PLATELET ACTIVATION BIOMARKERS.
Analyses of plasma sCD40L and sP-selectin levels
and serum TxB2 were repeated at the end of hospi-
talization (within approximately 10 days of hospital
admission). Compared with baseline values, all of
the variables significantly decreased, independent
of ASA use (Figure 4).
DISCUSSION
In this study, we prospectively analyzed the inci-
dence of MI in patients hospitalized for CAP. The
novel findings of the study are as follows: 1) in the
early phase of pneumonia (within 48 h of presenta-
tion), patients showed elevated hs-cTnT, which may
be either isolated or MI associated; 2) MI was not
associated with chest pain in the majority of cases;
3) the severity of pneumonia, as assessed by PSI score
and ejection fraction, was independently associated
with MI; 4) in vivo platelet activation and over-
production of serum TxB2 formation were indepen-
dently associated with MI; and 5) ASA 100 mg/day
seemed insufficient for preventing serum TxB2
overproduction.Previous studies showed that pneumonia is
complicated by elevated hs-cTnT values, indicating
an association between infectious disease and myo-
cardial injury. Notably, Chang et al. (5) recently re-
ported that 19% of patients with pneumonia have
elevated hs-cTnT values at admission. We found that
elevated hs-cTnT was even more prevalent in our
population; hs-cTnT was elevated in >50%. This dif-
ference may be because we measured hs-cTnT levels
not only at baseline but also every 12 h during the
first days of hospitalization. Increased hs-cTnT was
detectable up to 48 h from hospital admission,
TABLE 2 Adjusted ORs for MI According to Selected Variables
on the Basis of Logistic Regression Analysis
Variable OR
95% CI
p Value VIF*Lower Upper
sCD40L >6.0 ng/ml 1.234 1.147 1.327 <0.001 1.129
sP-selectin >26 ng/ml 1.233 1.142 1.330 <0.001 1.217
TxB2 >200 ng/ml 1.084 1.008 1.166 0.030 1.035
MPV 1.025 1.002 1.048 0.037 1.056
Ejection fraction 0.994 0.991 0.998 0.001 1.150
PSI score 1.001 1.001 1.002 0.030 1.254
After adjusting for age, sex, BMI, history of CHD, previous stroke, T2DM, hyper-
tension, renal failure, COPD, CAF, PAF, PAD, dyslipidemia, platelet count, hs-CRP,
use of statins, and ASA. *Given that all VIFs are well below the cutoff, the pa-
rameters can be directly interpreted, and there are no collinearity issues.
CI ¼ confidence interval; OR ¼ odds ratio; VIF ¼ variance inflation factor; other
abbreviations as in Table 1.
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1922indicating that myocardial damage should be inves-
tigated in the early phase of hospitalization.
Among patients with elevated hs-cTnT, 31 were
diagnosed as affected by MI, yielding an 11% intra-
hospital incidence of MI. Although previous studies
showed that pneumonia may be complicated byMI (2),
those were mostly retrospective studies, and the rate
of MI ranged from as low as 0.8% to as high as 10.7%
(21–24). In the only prospective study reported thus
far, Corrales-Medina et al. (4) found a 3.6% rate during
a follow-up period of 7 days. In the present study, we
found a higher MI rate, likely because we measured
hs-cTnT, a more sensitive marker of myocardial ne-
crosis, and because we monitored hs-cTnT values
daily, along with electrocardiography. Moreover, our
hospitalized patients were older, had a higher preva-
lence of comorbidities, and had higher PSI scores.600
500
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0
ASA-Untreated Patients ASA-Treated Patients
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m
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Patients with MI
FIGURE 3 Thromboxane B2 Levels in ASA-Untreated and
ASA-Treated Patients Who Did or Did Not Experience MIs
*p ¼ 0.001; **p ¼ 0.005. ASA ¼ acetylsalicylic acid;
MI ¼ myocardial infarction.MI usually occurred within 48 h of clinical pre-
sentation, consistent with the study by Corrales-
Medina et al. (2), who found that more than 50% of
cardiovascular complications occurred within 24 h of
presentation. The peculiarity of our methodological
approach turned out to be particularly useful,
because almost all patients with pneumonia had si-
lent MIs; without daily monitoring of cardiac tropo-
nins and electrocardiography, it would not be
possible to fully appreciate the occurrence of MI.
Among the clinical variables analyzed, age, PSI score,
ejection fraction, history of CHD, previous stroke, and
hypertension were associated with MI. However, in
multivariate analysis, only PSI and ejection fraction
were independently associated with MI. Of note, pa-
tients with a mean PSI score of 120 were at higher risk
for MI. Our observation of an association between
MI and history of CHD in 65% of patients who expe-
rienced MI is also interesting and suggests that
patients with underlying CHD are more susceptible
to MI after pneumonia.
Few studies have analyzed platelet behavior in
pneumonia. Patients with MI complicated by pneu-
monia displayed platelet hyperaggregation and non-
response to ASA more than patients with MI
without pneumonia, suggesting that lung infection
could trigger platelet activation (27,28). Additionally,
Kreutz et al. (29) found higher platelet aggregation in
patients affected by viral upper respiratory tract in-
fections compared with controls. The interplay be-
tween platelet activation and MI in a population
affected by pneumonia had never been examined.
We report for the first time that in vivo platelet
activation, as assessed by plasma levels of sCD40L
and sP-selectin, was independently associated with
MI. TxB2 overproduction accompanied in vivo plate-
let activation, which was also independently associ-
ated with MI. Even if this suggests a role for
COX1 activation in enhancing platelet activation,
platelet TxB2 overproduction is unlikely to be the
only mechanism for platelet activation, as serum
TxB2 was only weakly correlated with sCD40L and
sP-selectin.
Previous studies demonstrated that an increased
platelet count was more predictive of clinical out-
comes in patients with CAP than leukocyte count
abnormalities (30). However, we did not observe any
differences in platelet count between patients with or
without MIs; conversely, MPV was both significantly
higher in patients with MIs and an independent pre-
dictor, consistent with previous studies showing that
MPV is independently associated with MI (31).
Bacteria may activate platelets; thus, the asso-
ciation between pneumonia and in vivo platelet
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FIGURE 4 In Vivo Platelet Activation Markers at
Hospital Admission and at the End of Hospitalization
Plasma levels of soluble CD40 ligand (sCD40L) (A), soluble
P-selectin (sP-selectin) (B), and serum thromboxane B2 (C)
at hospital admission and at the end of hospitalization in acetylsa-
licylic acid (ASA)–untreated and ASA-treated patients. *p <0.001.
Cangemi, R., et al., J Am Coll Cardiol. 2014; 64(18):1917–25.
CENTRAL ILLUSTRATION Potential Mechanisms for Platelet Activation
During Pneumonia
Platelets can interact directly with bacteria or with lipopolysaccharide (LPS)
(an endotoxin) on the surface of Gram-negative bacteria by a Toll-like receptor 4
(TLR4)–mediated mechanism; this results in platelet activation and aggregation and,
eventually, thrombus formation. sCD40L ¼ soluble CD40 ligand; sP-selectin ¼ soluble
P-selectin.
J A C C V O L . 6 4 , N O . 1 8 , 2 0 1 4 Cangemi et al.
N O V E M B E R 4 , 2 0 1 4 : 1 9 1 7 – 2 5 Platelet Activation and MI in Pneumonia
1923activation is biologically plausible. In particular,
bacteria-platelet interaction may occur via bacteria
binding to platelets, either directly, through a bacte-
rial surface protein, or indirectly by a plasma-bridging
molecule linking bacterial and platelet surfacereceptors (28). However, whether either a specific
agent or the infection burden is implicated in platelet
activation and, eventually, coronary thrombosis re-
mains to be explored (28). In this context, the role of
endotoxins should be examined, as there is evidence
to support a role for endotoxins as platelet stimula-
tors via Toll-like receptor 4 (32,33) (Central
Illustration). An intriguing finding of the present
study was that although patients on ASA treatment
showed lower serum TxB2 compared with nonusers,
serum TxB2 in ASA-treated patients was persistently
elevated, suggesting that low-dose ASA was insuffi-
cient to fully inhibit COX1. Accordingly, many pa-
tients on ASA had values of serum TxB2 >10 ng/ml,
while optimal long-term ASA treatment is usually
associated with serum TxB2 <10 ng/ml (26). Further-
more, ASA-treated patients who experienced MIs had
significantly higher serum TxB2 than ASA-treated
patients who did not experience MIs.
Among the whole study population, 113 patients
(41%) displayed elevated hs-cTnT not associated with
electrocardiographic changes, which were considered
isolated hs-cTnT elevation. Isolated elevation of hs-
cTnT can be detected in several clinical settings not
associated with MI, including infections and sepsis,
and is usually considered a specific marker of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Elderly patients are at risk for developing myocardial
ischemia and infarction early in the course of CAP.
Elevated platelet activation markers and thromboxane
A2 generation in these patients suggest that platelets
play a role in the pathogenesis of these cardiac
events.
TRANSLATIONAL OUTLOOK: Future studies
should address the safety and efficacy of adminis-
tering ASA or other antiplatelet drugs to patients
presenting with acute CAP.
Cangemi et al. J A C C V O L . 6 4 , N O . 1 8 , 2 0 1 4
Platelet Activation and MI in Pneumonia N O V E M B E R 4 , 2 0 1 4 : 1 9 1 7 – 2 5
1924myocardial injury (34). Even if elevated hs-cTnT is a
marker of poor prognosis (35), its use for diagnosis
and management in settings unrelated to acute cor-
onary syndrome is still evolving (34). Of note, with
the exception of a weak correlation with sP-selectin,
neither sCD40L nor serum TxB2 was correlated with
isolated hs-cTnT.
STUDY LIMITATIONS. The study had limitations and
implications. Because CAP affected our population,
the data cannot be extrapolated to other types of
pneumonia. The mechanism accounting for platelet
activation is not fully clarified by the present study;
however, the correlation between serum TxB2 and
the 2 markers of platelet activation suggests that
platelet TxB2 overproduction might play a role. We
also did not investigate if pneumonia was of bacterial
or viral origin or if specific pathogens or systemic
inflammation were responsible for platelet activation
and platelet TxB2 overproduction. However, acute
infection per se is likely to be implicated, as in vivo
platelet activation and serum TxB2 significantly de-
creased at hospital discharge, independent of ASA
use. Finally, we have no explanation for MI being
silent in patients with pneumonia, and further study
should be done to clarify this phenomenon. We
cannot exclude that an imbalance between myocar-
dial oxygen supply and demand was the primary
cause of MI in many of our critically ill patients
(i.e., MI type 2 according to the universal definition
[18]). Therefore, further study in an even larger
population is needed to better appreciate the rate of
MI in this setting.
An important implication of this study is that in
patients with severe pneumonia, such as those with
PSI scores of approximately 120, corresponding to
classes IV and V (14), or prior CHD, daily monitoring
of cardiac troponins and electrocardiography is
necessary to detect MI, as MI was rarely associated
with chest pain. Such monitoring should be done
immediately after pneumonia diagnosis, as MI
generally occurred within 48 h of presentation.
Another important issue raised by this study is the
inefficacy of ASA 100 mg/day in completely prevent-
ing serum TxB2 formation in patients with pneu-
monia, suggesting that this dosage does not fully
inhibit COX-1. In other clinical settings, it is becoming
evident that because of accelerated platelet turnover,a dose of 100 mg ASA twice daily is more effective
than ASA 100 mg/day to fully prevent platelet TxB2
(36). We cannot exclude that a similar phenomenon
may also occur in pneumonia and that another ASA
regimen should therefore be adopted in this clinical
setting. However, we cannot exclude that the
persistent platelet TxB2 elevation, despite ASA treat-
ment, observed at baseline, may result from lowered
ASA bioavailability or poor compliance (37).
CONCLUSIONS
We provide evidence that >50% of patients with
pneumonia had hs-cTnT elevation, which was iso-
lated or associated with MI in about 11% of cases.
Because MI was silent in the majority of cases, daily
monitoring of troponins and electrocardiography is
needed for detection. Platelet activation was signifi-
cantly associated with MI, suggesting a role for
platelets in triggering coronary thrombosis. Daily 100-
mg doses of ASA were unable to prevent platelet TxB2
formation. Future studies should be done to identify
a more appropriate ASA dose to fully block COX1,
thus preventing serum TxB2 overproduction in pa-
tients with pneumonia.
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